
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6998055/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ciliary neurotrophic factor is increased in the plasma of patients with obesity and its levels correlate with diabetes and inflammation indices. Scientific Reports, 2022, 12, 8331.	3.3	3
2	The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents. International Journal of Molecular Sciences, 2022, 23, 5617.	4.1	2
3	Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. Cardiovascular Diabetology, 2022, 21, .	6.8	25
4	Randomized, Double-Blind, Placebo-Controlled Trial to Test the Effects of a Nutraceutical Combination Monacolin K-Free on the Lipid and Inflammatory Profile of Subjects with Hypercholesterolemia. Nutrients, 2022, 14, 2812.	4.1	6
5	Plasma levels of interleukin-38 in healthy aging and in type 2 diabetes. Diabetes Research and Clinical Practice, 2021, 171, 108585.	2.8	13
6	CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. Diabetes, 2021, 70, 240-254.	0.6	38
7	Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer's disease in comparison with healthy aging. GeroScience, 2021, 43, 985-1001.	4.6	36
8	Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 647015.	3.4	22
9	Nutraceutical Combinations in Hypercholesterolemia: Evidence from Randomized, Placebo-Controlled Clinical Trials. Nutrients, 2021, 13, 3128.	4.1	4
10	<p>Preserving Mobility in Older Adults with Physical Frailty and Sarcopenia: Opportunities, Challenges, and Recommendations for Physical Activity Interventions</p> . Clinical Interventions in Aging, 2020, Volume 15, 1675-1690.	2.9	100
11	Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1696-1700.	4.4	40
12	Effects of a novel nutraceutical combination (BruMeCholâ"¢) in subjects with mild hypercholesterolemia: study protocol of a randomized, double-blind, controlled trial. Trials, 2020, 21, 616.	1.6	9
13	Mild Cognitive Impairment Subtypes and Type 2 Diabetes in Elderly Subjects. Journal of Clinical Medicine, 2020, 9, 2055.	2.4	10
14	The microRNA-34a-Induced Senescence-Associated Secretory Phenotype (SASP) Favors Vascular Smooth Muscle Cells Calcification. International Journal of Molecular Sciences, 2020, 21, 4454.	4.1	21
15	Small extracellular vesicles deliver miRâ€21 and miRâ€217 as proâ€senescence effectors to endothelial cells. Journal of Extracellular Vesicles, 2020, 9, 1725285.	12.2	104
16	Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial. Nutrients, 2020, 12, 1098.	4.1	26
17	NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2019, 8, 720.	2.4	52
18	Circulating miR-146a in healthy aging and type 2 diabetes: Age- and gender-specific trajectories. Mechanisms of Ageing and Development, 2019, 180, 1-10.	4.6	64

#	Article	IF	CITATIONS
19	Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging. Aging, 2019, 11, 1648-1663.	3.1	32
20	Genes associated with Type 2 Diabetes and vascular complications. Aging, 2018, 10, 178-196.	3.1	37
21	Tenâ€year changes in ambulatory blood pressure: The prognostic value of ambulatory pulse pressure. Journal of Clinical Hypertension, 2018, 20, 1230-1237.	2.0	18
22	Glycated albumin: correlation to HbA _{1c} and preliminary reference interval evaluation. Clinical Chemistry and Laboratory Medicine, 2017, 55, e31-e33.	2.3	20
23	The "Metabolic Memory―Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients, 2017, 9, 437.	4.1	169
24	Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM. Oncotarget, 2017, 8, 93338-93348.	1.8	21
25	The Possible Role of Flavonoids in the Prevention of Diabetic Complications. Nutrients, 2016, 8, 310.	4.1	111
26	Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. Cardiovascular Diabetology, 2016, 15, 71.	6.8	66
27	The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes. Diabetes Research and Clinical Practice, 2016, 114, 64-68.	2.8	8
28	Special considerations for the treatment of chronic kidney disease in the elderly. Expert Review of Clinical Pharmacology, 2016, 9, 727-737.	3.1	5
29	Focus on migrants with type 2 diabetes mellitus in European Countries. Internal and Emergency Medicine, 2016, 11, 319-326.	2.0	28
30	Effectiveness of citrate buffer-fluoride mixture in Terumo tubes as an inhibitor of in vitro glycolysis. Biochemia Medica, 2016, 26, 68-76.	2.7	18
31	Leukocyte telomere length and mortality risk in patients with type 2 diabetes. Oncotarget, 2016, 7, 50835-50844.	1.8	44
32	Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clinical Epigenetics, 2015, 7, 56.	4.1	83
33	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget, 2015, 6, 35372-35382.	1.8	107
34	N-Glycomic Changes in Serum Proteins in Type 2 Diabetes Mellitus Correlate with Complications and with Metabolic Syndrome Parameters. PLoS ONE, 2015, 10, e0119983.	2.5	81
35	The Report-AGE project: a permanent epidemiological observatory to identify clinical and biological markers of health outcomes in elderly hospitalized patients in Italy. Aging Clinical and Experimental Research, 2015, 27, 893-901.	2.9	15
36	Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factorâ€ <i>α</i> inhibitors: results of a retrospective analysis. International Journal of Dermatology, 2015, 54, 839-845.	1.0	65

#	Article	IF	CITATIONS
37	Diabetesâ€related quality of life is enhanced by glycaemic improvement in older people. Diabetic Medicine, 2015, 32, 243-249.	2.3	9
38	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging, 2014, 6, 771-786.	3.1	105
39	Evidences of +896 A/G TLR4 Polymorphism as an Indicative of Prevalence of Complications in T2DM Patients. Mediators of Inflammation, 2014, 2014, 1-8.	3.0	15
40	Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 116-123.	2.6	41
41	The UP-TECH project, an intervention to support caregivers of Alzheimer's disease patients in Italy: study protocol for a randomized controlled trial. Trials, 2013, 14, 155.	1.6	28
42	The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study. Acta Diabetologica, 2013, 50, 429-436.	2.5	28
43	Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects. Nephrology Dialysis Transplantation, 2013, 28, 964-971.	0.7	18
44	Centenarians as super-controls to assess the biological relevance of genetic risk factors for common age-related diseases: A proof of principle on type 2 diabetes. Aging, 2013, 5, 373-385.	3.1	57
45	Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes. Diabetes, 2012, 61, 2993-2997.	0.6	136
46	Mitochondrial DNA Backgrounds Might Modulate Diabetes Complications Rather than T2DM as a Whole. PLoS ONE, 2011, 6, e21029.	2.5	74
47	Leukocyte telomere length is associated with complications of Type 2 diabetes mellitus. Diabetic Medicine, 2011, 28, 1388-1394.	2.3	89
48	The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance―to Glucagon-Like Peptide 1 in Diabetes. Diabetes Care, 2011, 34, 697-702.	8.6	119
49	Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications. Current Pharmaceutical Design, 2010, 16, 898-903.	1.9	18
50	In the Light of the Metabolic Memory Theory, Should Not All Aged People with Dysglycemia Be Treated?. Rejuvenation Research, 2010, 13, 599-605.	1.8	4
51	The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing. Mechanisms of Ageing and Development, 2009, 130, 497-500.	4.6	11
52	Variations at the H-strand replication origins of mitochondrial DNA and mitochondrial DNA content in the blood of type 2 diabetes patients. Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 547-552.	1.0	13
53	Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. Atherosclerosis, 2009, 206, 588-593.	0.8	81
54	C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position â''675 of the PAI-1 gene. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 220-226.	2.6	9

#	Article	IF	CITATIONS
55	+647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Molecular Genetics and Metabolism, 2008, 94, 98-104.	1.1	74
56	Glucose "peak―and glucose "spike― Impact on endothelial function and oxidative stress. Diabetes Research and Clinical Practice, 2008, 82, 262-267.	2.8	90
57	Effect of Etanercept on Insulin Sensitivity in Nine Patients with Psoriasis. International Journal of Immunopathology and Pharmacology, 2007, 20, 731-736.	2.1	90
58	Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histology and Histopathology, 2007, 22, 1109-18.	0.7	26
59	Interleukin-6–174 G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Research and Clinical Practice, 2006, 71, 299-305.	2.8	50
60	Interleukin-6 is a determinant of PAI-1 levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene. Thrombosis and Haemostasis, 2006, 95, 587-588.	3.4	1
61	Paraoxonase Activity and Genotype Predispose to Successful Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 541-546.	3.6	34
62	Asymptomatic Helicobacter pylori Infection Increases Asymmetric Dimethylarginine Levels in Healthy Subjects. Helicobacter, 2005, 10, 609-614.	3.5	15
63	High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Analytical Biochemistry, 2003, 318, 13-17.	2.4	63
64	Helicobacter pylorimasks differences in homocysteine plasma levels between controls and type 2 diabetic patients. European Journal of Clinical Investigation, 2002, 32, 158-162.	3.4	14
65	Fast, simple and cost-effective determination of thiopental in human plasma by a new HPLC technique. Clinica Chimica Acta, 2001, 305, 41-45.	1.1	9
66	Critical Role of pH for Derivatization of Homocysteine with Benzofurazanes. Clinical Chemistry, 2001, 47, 2157-2159.	3.2	1
67	Age-Dependent Changes of Serum Oxygen Radical Scavenger Capacity and Haemoglobin Glycosylation in Non-Insulin-Dependent Diabetic Patients. Gerontology, 2001, 47, 88-92.	2.8	11
68	Relationship between lipoprotein(a) levels, oxidative stress, and blood pressure levels in patients with essential hypertension. Clinical and Experimental Medicine, 2001, 1, 145-150.	3.6	17
69	Determination of Plasma Metformin by a New Cation-Exchange HPLC Technique. Therapeutic Drug Monitoring, 1999, 21, 330.	2.0	33
70	A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications. International Journal of Clinical and Laboratory Research, 1998, 28, 187-191.	1.0	2
71	Determination of Vanillylmandelic, 5-Hydroxyindoleacetic and Homovanillic Acid in Urine by Isocratic Liquid Chromatography. Clinical Chemistry and Laboratory Medicine, 1997, 35, 57-61.	2.3	3
72	Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice, 1996, 33, 111-118.	2.8	23

#	Article	IF	CITATIONS
73	Glycosylated hemoglobin and fructosamines: does their determination really reflect the glycemic control in diabetic patients?. Life Sciences, 1996, 59, 43-49.	4.3	16
74	Adrenaline effects on the oxygen binding to trout hemoglobin. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1991, 98, 451-453.	0.2	4
75	Oxidative hemolysis in erythrocytes with unstable hemoglobins. Clinica Chimica Acta, 1989, 185, 115-116.	1.1	1